PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14760072-6	2004	This latter point was confirmed in vivo, in a patient affected by CD26(-) T-cell receptor gammadelta(+) hepatosplenic gammadelta(+) T-cell lymphomas treated on a compassionate basis with dCF.	Pentostatin	187-190	dipeptidyl peptidase 4	Homo sapiens	66-133	
14760072-0	2004	CD26 expression correlates with a reduced sensitivity to 2"-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas.	Pentostatin	57-75	dipeptidyl peptidase 4	Homo sapiens	0-4	
14760072-3	2004	Once the surface expression of CD26 and ADA in a panel of cell lines and primary samples of T-cell leukemia/lymphoma was defined, we correlated this expression with the antiproliferative and apoptotic effect of dCF.	Pentostatin	211-214	dipeptidyl peptidase 4	Homo sapiens	31-35	
14760072-4	2004	RESULTS: Surface expression of CD26 inversely correlated with the capability of dCF to inhibit cell growth and induce apoptosis both in T-cell lines and primary samples of T-cell malignancies.	Pentostatin	80-83	dipeptidyl peptidase 4	Homo sapiens	31-35	
14760072-7	2004	The inverse correlation between CD26 expression and sensitivity to dCF was also demonstrated in a lymphoblastic lymphoma case in which CD26 was expressed on circulating blasts at relapse but not at diagnosis, as well as in two H9 T-cell clones expressing or not expressing CD26 mRNA and protein.	Pentostatin	67-70	dipeptidyl peptidase 4	Homo sapiens	32-36	
14760072-7	2004	The inverse correlation between CD26 expression and sensitivity to dCF was also demonstrated in a lymphoblastic lymphoma case in which CD26 was expressed on circulating blasts at relapse but not at diagnosis, as well as in two H9 T-cell clones expressing or not expressing CD26 mRNA and protein.	Pentostatin	67-70	dipeptidyl peptidase 4	Homo sapiens	135-139	
14760072-7	2004	The inverse correlation between CD26 expression and sensitivity to dCF was also demonstrated in a lymphoblastic lymphoma case in which CD26 was expressed on circulating blasts at relapse but not at diagnosis, as well as in two H9 T-cell clones expressing or not expressing CD26 mRNA and protein.	Pentostatin	67-70	dipeptidyl peptidase 4	Homo sapiens	135-139	
14760072-8	2004	CONCLUSIONS: This study corroborates the notion of CD26 as a marker of poor prognosis for T-cell malignancies and delineates a role for CD26 as a predictor of poor response to dCF.	Pentostatin	176-179	dipeptidyl peptidase 4	Homo sapiens	136-140	
12883733-0	2003	Pentostatin in T-non-Hodgkin"s lymphomas: efficacy and effect on CD26+ T lymphocytes.	Pentostatin	0-11	dipeptidyl peptidase 4	Homo sapiens	65-69	
12883733-4	2003	We also examined the lymphopenic effect of pentostatin on CD26+ T lymphocytes.	Pentostatin	43-54	dipeptidyl peptidase 4	Homo sapiens	58-62	
12883733-11	2003	Pentostatin also specifically depleted CD26+ rather than CD26- T lymphocytes, potentially associated with immunosuppression.	Pentostatin	0-11	dipeptidyl peptidase 4	Homo sapiens	39-43	
12883733-11	2003	Pentostatin also specifically depleted CD26+ rather than CD26- T lymphocytes, potentially associated with immunosuppression.	Pentostatin	0-11	dipeptidyl peptidase 4	Homo sapiens	57-61	
12883733-12	2003	We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications.	Pentostatin	33-44	dipeptidyl peptidase 4	Homo sapiens	140-144	
10887640-5	2000	This trial will evaluate the effect of pentostatin (Nipent), a potent adenosine deaminase inhibitor with known efficacy against T-cell malignancies, on relapsed/refractory T-cell lymphomas in relation to CD26 expression.	Pentostatin	39-50	dipeptidyl peptidase 4	Homo sapiens	204-208	
8986139-0	1996	Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase.	Pentostatin	10-25	dipeptidyl peptidase 4	Homo sapiens	95-99